<DOC>
	<DOCNO>NCT00910091</DOCNO>
	<brief_summary>This trial explore safety efficacy BN83485 compare Megestrol Acetate ( MA ) progression free survival ( PFS ) post menopausal patient endometrial cancer .</brief_summary>
	<brief_title>The Study Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate ( MA ) Women With Advanced Recurrent Endometrial Cancer</brief_title>
	<detailed_description>The Primary Objective study determine antitumour efficacy BN83495 measure percentage woman advance recurrent endometrial cancer neither progress die 6 month treatment .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Megestrol</mesh_term>
	<mesh_term>Megestrol Acetate</mesh_term>
	<criteria>Provision write informed consent prior study related procedure Postmenopausal ovariectomised female patient age 18 year advance recurrent endometrial carcinoma Histologically confirm diagnosis endometrial carcinoma ( primary tumour metastasis ) Not eligible surgery radiotherapy alone , Investigator 's discretion Documented Estrogen Receptor ( ER ) positivity primary tumour metastatic tissue primary tumour unavailable ( ER positivity define least 10 % positive cell ) No history malignant disease except treat basal cell situ cervical carcinoma previous 5 year . In case previous malignant disease , pathological confirmation metastatic endometrial cancer do Investigator 's discretion Eastern Cooperative Oncology Group ( ECOG ) Performance status ≤2 At least one measurable disease site minimum indicator lesion size : 20 mm ( conventional technique ) 10 mm ( spiral CT scan ) target lesion situate irradiated area Life expectancy ≥6 month Adequate organ function define follow criterion : Haemoglobin ≥10 g/dL Absolute neutrophil count ( ANC ) ≥1500/μL Platelets ≥100,000/μL Serum creatinine ≤1.5x upper limit normal ( ULN ) calculate creatinine clearance ≥50 ml/min Serum AST serum ALT ≤2.5x ULN AST ALT ≤5x ULN liver metastasis Total serum bilirubin ≤1.5x ULN Serum albumin ≥3.0 g/dL Cardiac function ≤New York Heart Association ( NYHA ) class II Patients must recover surgery , radiotherapy toxicity adjuvant chemotherapy treatment applicable Patients must willing able participate clinical trial ( include completion necessary study procedure ) Patients must able swallow oral medication Use investigational agent 4 week prior enrollment study Prior systemic treatment endometrial cancer ( include hormonal treatment , chemotherapy , antiangiogenic targeted therapy ) exception chemotherapy adjuvant setting , complete least 6 month prior randomisation Known central nervous system ( CNS ) metastases Ongoing cardiac dysrhythmias National Cancer Institute Common Toxicity Criteria Adverse Events ( NCI CTC AE ) grade ≥2 , atrial fibrillation grade , QTcF interval &gt; 460 msec . Patients contraindication Megestrol Acetate ( MA ) include hypersensitivity one drug product , active arterial venous thromboembolic event and/or uncontrolled hypertension . Patients receive anticoagulation prior thromboembolic event may enrol study Investigator 's discretion Concomitant use carbonic anhydrase II inhibitor ( e.g . acetazolamide , dichlorphenamide , methazolamide ) History hypersensitivity BN83495 drug similar chemical structure Likely require treatment study drug permit study protocol Abnormal baseline finding , medical condition ( ) laboratory finding , opinion Investigator , might jeopardise patient 's safety decrease chance obtain satisfactory data need achieve objective ( ) study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Endometrial cancer</keyword>
	<keyword>Antitumour efficacy woman advance endometrial cancer</keyword>
</DOC>